<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(19)</volume><submitter>Chi X</submitter><pubmed_abstract>In pursuit of developing novel azole antifungals with potent activity and high selectivity, a series of (2&lt;i>R&lt;/i>,3&lt;i>S&lt;/i>)-3-(substituted-1&lt;i>H&lt;/i>-pyrazol-3-yl)-2-(2,4-difluorophenyl)-1-(1&lt;i>H&lt;/i>-tetrazol-1-yl)butan-2-ol derivatives were designed and synthesized based on our previous work. All compounds exhibited excellent &lt;i>in vitro&lt;/i> antifungal activities against &lt;i>Candida&lt;/i> spp. and &lt;i>Cryptococcus neoformans&lt;/i> H99 with minimum inhibitory concentration values ranging from &lt;0.008 to 4 μg/mL, with some even showing moderate activity against &lt;i>Aspergillus fumigatus&lt;/i> 7544. The most active compounds (&lt;b>8&lt;/b>, &lt;b>11&lt;/b>, &lt;b>15&lt;/b>, &lt;b>24&lt;/b>, and &lt;b>25)&lt;/b> displayed outstanding antifungal activity against six fluconazole-resistant &lt;i>C. auris&lt;/i> clinical isolates and showe</pubmed_abstract><journal>ACS omega</journal><pagination>17103-17115</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10193422</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Discovery of Novel Tetrazoles Featuring a Pyrazole Moiety as Potent and Highly Selective Antifungal Agents.</pubmed_title><pmcid>PMC10193422</pmcid><pubmed_authors>Jiang Y</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Ni T</pubmed_authors><pubmed_authors>Chi X</pubmed_authors><pubmed_authors>Li L</pubmed_authors><pubmed_authors>Wu H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Discovery of Novel Tetrazoles Featuring a Pyrazole Moiety as Potent and Highly Selective Antifungal Agents.</name><description>In pursuit of developing novel azole antifungals with potent activity and high selectivity, a series of (2&lt;i>R&lt;/i>,3&lt;i>S&lt;/i>)-3-(substituted-1&lt;i>H&lt;/i>-pyrazol-3-yl)-2-(2,4-difluorophenyl)-1-(1&lt;i>H&lt;/i>-tetrazol-1-yl)butan-2-ol derivatives were designed and synthesized based on our previous work. All compounds exhibited excellent &lt;i>in vitro&lt;/i> antifungal activities against &lt;i>Candida&lt;/i> spp. and &lt;i>Cryptococcus neoformans&lt;/i> H99 with minimum inhibitory concentration values ranging from &lt;0.008 to 4 μg/mL, with some even showing moderate activity against &lt;i>Aspergillus fumigatus&lt;/i> 7544. The most active compounds (&lt;b>8&lt;/b>, &lt;b>11&lt;/b>, &lt;b>15&lt;/b>, &lt;b>24&lt;/b>, and &lt;b>25)&lt;/b> displayed outstanding antifungal activity against six fluconazole-resistant &lt;i>C. auris&lt;/i> clinical isolates and showe</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2025-04-26T21:30:36.745Z</modification><creation>2025-04-06T16:47:43.654Z</creation></dates><accession>S-EPMC10193422</accession><cross_references><pubmed>37214706</pubmed><doi>10.1021/acsomega.3c01421</doi></cross_references></HashMap>